Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Looking for ways teens can make cash fast? Here are some quick ideas to help you start earning money today.
28,072 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
CrowdStrike faced a sharp sell-off for a second consecutive day after a sector-wide reaction to new AI security produ...
A viral parody drawing 110 million views isn’t just a pop culture moment—it also tests money decisions. This guide sh...
AI chip headlines are steering market moves this June. From Google’s foundry ambitions to Intel's refreshed strategy,...
PepsiCo drives growth with international momentum while Procter & Gamble shines in beauty; both set the stage for a d...
CrowdStrike’s ARR growth has reaccelerated, but does that make the stock a buy? This guide breaks down ARR health, ma...
Cerebras stock is catching attention this week as analysts initiate coverage and AI demand grows. This article breaks...
As investors weigh a high-priced AR launch, the stock market today, june shows how one product can ripple across sent...
Wendy's stock jumped on a viral meme rally, but a quick price spike is only part of the story. This article breaks do...
If you’re chasing a steadier, growing paycheck from healthcare stocks, CVS Health and UnitedHealth Group deserve a cl...
As DNOW readies its 2025 earnings narrative, investors should focus on backlog, free cash flow, and guidance. This gu...
While tech and AI grab headlines, other parts of the market are quietly delivering solid results. This piece explores...